The agreements are for the development and validation of microRNA-based diagnostics for various indications related to its Gen 3 products.

The Gen 3 tests will focus on cardiovascular indications, neurodegenerative diseases, women’s health and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.

The collaborations are an integral part of Rosetta Genomics‘ Gen 3 product development process as they leverage the capabilities and samples at specialized centers to identify initial microRNA candidate biomarkers for the company’s discovery-stage projects.